Molecular Templates Provides Corporate Update and Outlines 2020 Milestones. Status updates and expected 2020 milestones: The potentially pivotal Phase 2 monotherapy DLBCL study is ongoing and is planned to enroll up to 100 patients. MTEM expects to announce updates on interim clinical results from this study and the ongoing lenalidomide and GemOx combination studies throughout 2020.